Form 4: MaxCyte CFO Douglas Swirsky Reports Stock and Option Awards

Douglas Swirsky, CFO of MaxCyte, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• Douglas J. Swirsky, the Chief Financial Officer of MaxCyte, Inc., filed a Form 4 on March 18, 2025.
• The report details changes in his beneficial ownership of MaxCyte's securities.
• On March 14, 2025, Swirsky acquired 37,500 restricted stock units (RSUs) and was granted options to purchase 150,000 shares of common stock at an exercise price of $3.29.
• The RSUs vest 25% on March 14, 2026, and the remainder in three equal annual installments.
• The stock options also vest 25% on March 14, 2026, with the remainder vesting in 36 equal monthly installments.
• Following these transactions, Swirsky beneficially owns 118,750 shares of common stock and options to purchase 150,000 shares.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing detailing executive compensation. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Positives

• The grant of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedules for both the RSUs and stock options encourage long-term commitment from the CFO.

Future Outlook

The vesting schedules of the RSUs and stock options suggest an expectation of continued service and contribution from the CFO over the next several years.

Industry Context

Stock and option grants are a common form of executive compensation in the biotechnology industry, aligning management incentives with shareholder value creation.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice in publicly traded biotechnology companies like MaxCyte.
• Companies such as CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize similar equity-based compensation to incentivize their executives.
• The vesting schedules described are typical, designed to retain key personnel and align their interests with long-term shareholder value.

Stakeholder Impact

• The equity grants incentivize the CFO to work towards increasing shareholder value.
• Employees may view the grants as a positive sign of the company's commitment to its leadership.

Key Dates